Phase
Condition
Retinoblastoma
Neuroblastoma
Cancer (Pediatric)
Treatment
DNA Methylation
Whole Genome Sequencing
Targeted Panel Sequencing
Clinical Study ID
Ages < 25 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Age < 18 years Note: Individual patients aged 19 - 25 years old with a pediatric cancer, e.g., neuroblastoma, may be enrolled after discussion with, and at the discretion of, the Study Chair or their delegate.
Life expectancy >6 weeks at time of enrolment
Consent i. Signed and dated informed consent for study enrolment from participant aged ≥ 18 years or from parent/guardian of participant aged <18 years. ii. Separate signed and dated informed consent for understanding the role of germline testing and choice for the return of germline results.
Study Design
Study Description
Connect with a study center
Women's and Children's Hospital
Adelaide,
AustraliaActive - Recruiting
Queensland Children's Hospital
Brisbane,
AustraliaActive - Recruiting
Royal Hobart Hospital
Hobart,
AustraliaActive - Recruiting
Monash Children's Hospital
Melbourne,
AustraliaActive - Recruiting
Royal Children's Hospital
Melbourne,
AustraliaActive - Recruiting
John Hunter Children's Hospital
Newcastle,
AustraliaActive - Recruiting
Perth Children's Hospital
Perth,
AustraliaActive - Recruiting
Sydney Children's Hospital, Randwick
Sydney,
AustraliaActive - Recruiting
The Children's Hospital at Westmead
Sydney,
AustraliaActive - Recruiting
Starship Children's Hospital
Auckland, Grafton 1023
New ZealandActive - Recruiting
Christchurch Hospital
Christchurch, 8011
New ZealandSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.